Hikal

how big is Hikal?

As of October 2023, Hikal Ltd has a market capitalization of 4,609.00 Cr, with recent net sales of 1,859.80 Cr and a net profit of 90.80 Cr over the last four quarters. Shareholder's funds are 1,187.66 Cr, and total assets amount to 2,487.15 Cr as of March 2024.

Market Cap: Hikal Ltd has a market capitalization of 4,609.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 1,859.80 Cr. The sum of Net Profit for the same period is 90.80 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 1,187.66 Cr, while Total Assets amount to 2,487.15 Cr.

What is the bonus history of the Hikal?

Hikal Ltd announced a 1:2 bonus issue on June 22, 2018, with a record date of June 25, 2018, meaning shareholders received one additional share for every two shares held.

Hikal Ltd has a bonus history that includes a 1:2 bonus issue announced on June 22, 2018. The record date for this bonus was June 25, 2018. This means that for every two shares held, shareholders received one additional share as a bonus.

Who are the peers of the Hikal?

Hikal's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Aarti Drugs, Dishman Carbogen, Unichem Labs, and Gufic BioScience. In terms of performance, Divi's Lab leads with a 1-year return of 51.69%, while Hikal has a return of 31.90%.

Peers: The peers of Hikal are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Aarti Drugs, Dishman Carbogen, Unichem Labs., and Gufic BioScience.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Aarti Drugs, and Gufic BioScience, while Good management risk is found at Divi's Lab., Torrent Pharma, Hikal, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Hikal, Aarti Drugs, Dishman Carbogen, and the rest. In terms of Capital Structure, Excellent ratings are given to Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Average is noted for Hikal, and Good for Torrent Pharma, Aarti Drugs, Unichem Labs., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the lowest is Aarti Drugs at -3.71%. Hikal's own 1-year return is 31.90%, which is significantly higher than Aarti Drugs but lower than Divi's Lab. Additionally, Dishman Carbogen, Unichem Labs., and Gufic BioScience have negative six-month returns.

Who are in the management team of Hikal?

As of March 2023, Hikal's management team includes Jai Hiremath (Executive Chairman), Sameer Hiremath (Managing Director), and several non-executive and independent directors, overseeing the company's operations and strategic direction.

As of March 2023, the management team of Hikal includes the following individuals:<BR><BR>1. Jai Hiremath - Executive Chairman<BR>2. Sameer Hiremath - Managing Director<BR>3. Baba Kalyani - Non-Executive & Non-Independent Director<BR>4. Kannan Unni - Non-Executive & Independent Director<BR>5. Sugandha Hiremath - Non-Executive & Non-Independent Director<BR>6. Prakash V Mehta - Non-Executive & Independent Director<BR>7. Amit B Kalyani - Non-Executive & Non-Independent Director<BR>8. Ranjit Shahani - Non-Executive & Independent Director<BR>9. Shivani Bhasin Sachdeva - Non-Executive & Independent Director<BR>10. Rajasekhar Reddy - Company Secretary & Compliance Officer<BR>11. Shrikrishna K. Adivarekar - Independent Director<BR>12. Berjis Minoo Desai - Independent Director<BR>13. V R Kaundinya - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Hikal do?

Hikal Ltd is a small-cap company in the Pharmaceuticals & Biotechnology sector, specializing in chemical intermediates, specialty chemicals, and active pharma ingredients. As of March 2025, it reported net sales of ₹5,524 Cr and a net profit of ₹502 Cr, with a market cap of ₹4,278 Cr.

Overview:<BR>Hikal Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, engaged in the manufacturing of chemical intermediates, specialty chemicals, active pharma ingredients, and contract research activities.<BR><BR>History:<BR>Hikal Ltd was incorporated on July 8, 1988. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 5,524 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 502 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 4,278 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 47.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.34% <BR>Debt-Equity: 0.59 <BR>Return on Equity: 7.19% <BR>Price-to-Book: 3.40 <BR><BR>Contact Details:<BR>Address: 717/718 Maker Chamber V, 7th Floor Nariman Point Mumbai Maharashtra : 400021 <BR>Tel: 91-022-3926 7100/62770477 <BR>Email: secretarial@hikal.com/info@hikal.co <BR>Website: http://www.hikal.com

Who are the top shareholders of the Hikal?

The top shareholders of Hikal include Kalyani Investment Company Limited with 31.36%, followed by 76 Foreign Institutional Investors holding 5.69%, and mutual funds with a combined 2.93%. Individual investors own 16.57%, with Tata Mutual Fund - Tata Small Cap Fund being the largest public shareholder at 2.68%.

The top shareholders of Hikal include the promoters, who hold the majority of the shares. The promoter with the highest holding is Kalyani Investment Company Limited, which owns 31.36% of the company. Additionally, there are 76 Foreign Institutional Investors (FIIs) holding 5.69%, and mutual funds are represented by 7 schemes with a combined holding of 2.93%. The highest public shareholder is Tata Mutual Fund - Tata Small Cap Fund, which holds 2.68%. Individual investors collectively own 16.57% of the shares.

How has been the historical performance of Hikal?

Hikal's historical performance shows mixed results, with net sales peaking at 2,023.03 Cr in Mar'23 before declining to 1,859.80 Cr in Mar'25, while operating profit increased slightly to 333.40 Cr in Mar'25, despite decreases in profit before and after tax. Total assets and liabilities rose to 2,528.90 Cr in Mar'25, and cash flow from operating activities improved to 280.00 Cr.

Answer:<BR>The historical performance of Hikal shows a mixed trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Hikal's net sales have fluctuated, with a peak of 2,023.03 Cr in Mar'23, followed by a decline to 1,859.80 Cr in Mar'25. The total operating income mirrored this trend, reaching 2,023.03 Cr in Mar'23 and decreasing to 1,859.80 Cr in Mar'25. Raw material costs rose to 882.60 Cr in Mar'25 from 781.90 Cr in Mar'20, while total expenditure (excluding depreciation) decreased to 1,531.40 Cr in Mar'25 from 1,765.96 Cr in Mar'23. Operating profit (PBDIT) saw a slight increase to 333.40 Cr in Mar'25 from 262.48 Cr in Mar'23, although profit before tax dropped to 123.80 Cr in Mar'25 from 105.37 Cr in Mar'23. Profit after tax also decreased to 90.80 Cr in Mar'25 from 78.39 Cr in Mar'23. The company's total assets increased to 2,528.90 Cr in Mar'25 from 2,385.48 Cr in Mar'23, while total liabilities rose to 2,528.90 Cr in Mar'25 from 2,385.48 Cr in Mar'23. Cash flow from operating activities improved to 280.00 Cr in Mar'25 from 186.00 Cr in Mar'24, indicating a positive trend in cash generation. Overall, Hikal's financial performance reflects both challenges and improvements across various metrics over the years.

Is Hikal technically bullish or bearish?

As of December 3, 2025, Hikal's technical trend is mildly bearish, with mixed signals from indicators like the MACD and Bollinger Bands, suggesting a cautious outlook in the short term.

As of 3 December 2025, the technical trend for Hikal has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several key indicators. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The Bollinger Bands and moving averages are both mildly bearish on the weekly and daily time frames. The KST shows a mildly bullish signal on the weekly, while the monthly remains bearish. The Dow Theory also reflects a mildly bullish stance on the weekly but is bearish on the monthly. Overall, the indicators suggest a cautious outlook with a slight bearish bias in the short term.

Is Hikal overvalued or undervalued?

As of December 4, 2025, Hikal's valuation has shifted from attractive to fair, with a high PE ratio of 309.11 and significant underperformance at -35.04% year-to-date, indicating concerns about its growth prospects compared to peers like Sun Pharma and Cipla.

As of 4 December 2025, Hikal's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 309.11, an EV to EBITDA of 16.62, and a Price to Book Value of 2.61. In comparison to peers, Sun Pharma has a PE ratio of 37.78 and an EV to EBITDA of 24.99, while Cipla is rated attractive with a PE of 22.58 and an EV to EBITDA of 15.98, highlighting Hikal's significant overvaluation relative to its competitors.<BR><BR>Despite its fair valuation, Hikal has underperformed in the market, with a year-to-date return of -35.04% compared to the Sensex's 9.12%. This underperformance, coupled with a high PEG ratio of 0.00 and low ROE of 0.85%, suggests that investors may be cautious about the company's growth prospects moving forward.

When is the next results date for Hikal Ltd?

The next results date for Hikal Ltd is 11 February 2026.

The next results date for Hikal Ltd is scheduled for 11 February 2026.

Are Hikal Ltd latest results good or bad?

Hikal Ltd's latest results are concerning, showing a net loss of ₹34.90 crores for Q3 FY26, a 290.71% decline year-on-year, and a 29.68% drop in revenue to ₹318.50 crores. The company is facing significant operational challenges and financial instability, with a 45.17% decrease in stock value over the past year.

Hikal Ltd's latest results are concerning and indicate a significant decline in performance. The company reported a net loss of ₹34.90 crores for Q3 FY26, which represents a staggering 290.71% decrease year-on-year. Revenue also fell sharply by 29.68% to ₹318.50 crores, marking the lowest quarterly revenue since June 2024. <BR><BR>Operating margins have collapsed to just 2.28%, down from 16.61% in the same quarter last year, reflecting severe operational distress. This decline in profitability has led to two consecutive quarters of losses, totaling ₹57.30 crores, raising alarms about the company's financial health.<BR><BR>Additionally, Hikal's stock has plummeted 45.17% over the past year, and it is currently trading at ₹191.25, indicating significant investor concern over its deteriorating fundamentals. The company faces challenges in maintaining profitability amidst falling sales and rising operational costs, which have further strained its financial position.<BR><BR>Overall, the results suggest that Hikal Ltd is in a critical situation, struggling with operational challenges and financial instability.

Should I buy, sell or hold Hikal Ltd?

Has Hikal Ltd declared dividend?

Yes, Hikal Ltd has declared a dividend of 10% (0.8 per share) with an ex-date of February 17, 2026. Despite the dividend, the company has experienced significant price declines over various periods, resulting in modest total returns.

Hikal Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 0.8<BR>- Ex-date: 17 Feb 26<BR><BR>Dividend Yield: 0.37%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, Hikal Ltd experienced a price return of -11.18%, a dividend return of 0.08%, resulting in a total return of -11.1%.<BR><BR>Over the past 6 months, the company saw a price return of -16.63%, a dividend return of 0.39%, leading to a total return of -16.24%.<BR><BR>In the 1-year period, Hikal Ltd reported a price return of -39.05%, a dividend return of 0.29%, culminating in a total return of -38.76%.<BR><BR>For the 2-year period, the price return was -23.52%, with a dividend return of 0.78%, resulting in a total return of -22.74%.<BR><BR>In the 3-year timeframe, the company had a price return of -35.23%, a dividend return of 1.13%, which gave a total return of -34.1%.<BR><BR>Over the last 4 years, Hikal Ltd experienced a price return of -49.8%, a dividend return of 1.25%, leading to a total return of -48.55%.<BR><BR>Finally, in the 5-year period, the company achieved a price return of 27.87%, a dividend return of 4.15%, resulting in a total return of 32.02%.<BR><BR>Overall, while Hikal Ltd has declared a dividend, the total returns over various periods indicate significant price declines, particularly in the shorter terms, despite some recovery in the longer term. The dividend yield remains modest in comparison to the price performance.

Why is Hikal Ltd falling/rising?

As of 06-May, Hikal Ltd's stock price is rising to 211.60, reflecting a 7.66% increase. This rise is driven by strong investor interest, outperforming its sector, and an attractive valuation despite past challenges.

As of 06-May, Hikal Ltd's stock price is rising, currently at 211.60, reflecting a change of 15.05 or 7.66% increase. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 5.25% today and has been on a gaining streak for the last five days, accumulating a total return of 12.79% during this period. Additionally, the stock reached an intraday high of Rs 212.85, indicating strong buying interest.<BR><BR>Moreover, there has been a notable increase in investor participation, with delivery volume rising by 43.79% compared to the five-day average, suggesting heightened interest from retail investors. The overall performance of the Pharmaceuticals & Drugs sector, which gained 2.41%, also supports the positive sentiment surrounding Hikal Ltd.<BR><BR>Despite the stock's recent gains, it is important to note that it has faced significant challenges over the past year, with a return of -43.87% and a decline in profits by -66.4%. However, its current attractive valuation, trading at a discount compared to peers, and a relatively favorable return on capital employed (ROCE) of 4.1 may be contributing to the recent positive price movement.

Which are the latest news on Hikal?